Table 4.
Post-study treatment experience of patients with stable disease.
| Subject ID | Disease | ALT-801 dose level (mg/kg) | Time to progression (months)a | Survival (months)a |
|---|---|---|---|---|
| 1001 | RCC | 0.015 | 7.7+ b | 46.9+ c |
| 2002 | Neuroendocrine | 0.015 | 3.9 | 12.4 |
| 1004 | Prostate | 0.04 | 2.3+ d | 19.9+ d |
| 1005 | RCC | 0.04 | 1.4+ d | 1.4+ d |
| 1012 | RCC | 0.04 | 2.8 | 11.6 |
| 2004 | Head and Neck | 0.04 | 10.4 | 21.0 |
| 4005 | Melanoma | 0.04 | 5.0 | 12.4 |
| 1007 | RCC | 0.08 | 3.0 | 16.1 |
| 3001 | Melanoma | 0.08 | 29.0+ e | 29.0+ c |
| 4001 | Melanoma | 0.08 | 9.5 | 35.4+ c |
a
Contribution of post-study therapy, if any, not assessed
b
No recent tumor assessment available
c
Alive as of last report
d
Lost to follow-up
e
No evidence of disease as of last report